Answer
During Inaqovi treatment, patients, especially those with a history of cardiac disease, must be monitored for signs and symptoms of heart failure; safety and efficacy have not been established in patients with a history of severe congestive heart failure or clinically unstable cardiac disease, who were excluded from studies.
Sources for this answer
- Inaqovi 35 mg/100 mg film coated tabletsOtsuka Pharmaceuticals (UK) Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 2Document updated
Sources checked